Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on wallstreetbets Subreddit Page by MostCapital5741. In ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...